abrdn Life Sciences Investors Shares of Beneficial Interest (HQL)

FairStock Score: 53/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I view HQL not as an operating company but as a closed-end fund holding life-sciences equities. That means the usual moat question is different: the fund itself has no durable competitive advantage; any edge must come from abrdn's security selection. At the close on 2026-10-13, the price was $17.26. FairStock calculations show P/B of 0.94, so it trades slightly below book value, and a Graham Number of $52.49 implies a 67.12% margin of safety. The P/E of 2.60 and ROE of 41.42% look statistically cheap, but for a fund these can be distorted by realized gains, accounting, or distributions. The 12.98% dividend yield is headline-grabbing, though I would want to know how much is income versus return of capital. Financial health signals are mixed: ROCE is -0.61%, Piotroski F-Score is 0/9, and the FairStock score is 53/100. Beta is 0.73, suggesting lower volatility than the market. Growth is unquantifiable here: revenue and profit growth are N/A, and the Lynch category is none because there are only 0 years of filed results, not the required three. Without a longer record, I cannot call this a durable compounding machine. The deep-value case rests on the discount to book and the wide Graham gap; the bear case rests on weak quality signals and the possibility that the high distribution is not sustainable. I would demand more filed history before trusting the headline numbers.

In plain English: It is a closed-end fund that invests in life sciences and healthcare stocks. The data shows it trades below its stated book value and offers a very high dividend yield, but quality signals are weak or missing. Based on the supplied numbers, the price looks inexpensive relative to book value, though the fund is hard to judge without a longer track record.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer